Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Class of 2025
Hammarskjold High School
Superior Collegiate and Vocational Institute
Westgate Collegiate & Vocational Institute
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zai Lab Limited - American Depositary Shares
(NQ:
ZLAB
)
32.73
-1.35 (-3.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zai Lab Limited - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
January 17, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
January 15, 2025
From
Zai Lab Limited
Via
Business Wire
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
January 10, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Why Zai Lab (ZLAB) Stock Is Trading Higher
November 15, 2024
Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering.
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
February 18, 2025
Via
Benzinga
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
January 28, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
January 22, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
January 10, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
January 09, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in Investor Conference in January 2025
December 12, 2024
From
Zai Lab Limited
Via
Business Wire
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
December 05, 2024
Via
The Motley Fool
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
December 02, 2024
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients.
Via
Benzinga
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
December 02, 2024
From
Zai Lab
Via
Business Wire
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
November 27, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
November 21, 2024
From
Zai Lab
Via
Business Wire
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
November 18, 2024
From
Zai Lab Limited
Via
Business Wire
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
November 15, 2024
Via
Benzinga
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
November 14, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Proposed Public Offering of American Depositary Shares
November 13, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
November 12, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
November 11, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
October 29, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results
October 24, 2024
The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells.
Via
Investor's Business Daily
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
October 24, 2024
Via
Benzinga
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
October 24, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in November and December Investor Conferences
October 18, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
October 17, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
October 16, 2024
From
Zai Lab Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.